View more job listings or post a job
InnoAlliance Scientist/Sr Scientist of Bioanalysis & Biomarkers
Bioduro-Sundia Associate Director/Director in Laboratory Animal and Exploratory Toxicology
Variant Bio (Senior) Scientist - DMPK
Alturas Analytics Scientist 1
Eli Lilly and Company R-39973 Scientific Director ADME - Novel Modalities (Open)
FibroGen Director DMPK
Post a job


[Free Online] Diabetes and Obesity Treatments: Current and Emerging Landscapes of GLP-1, GIP, and Beyond

Speakers: Oliver Philps, PhD, medicinal chemist; Scott Morano, Ipsos
Organizers: Shichang Miao, PBSS; Dean Wilson, PBSS
Date: 2024-08-22
Time: 11:30-14:30 Pacific Time
Registration fee: 0
Location: Online via Zoom
Major Sponsor:
Vendor show vendors registered to date:
Registration deadline:2024-08-21  (it will close sooner if the seating cap is reached)

About the Topic

Glucagon-like peptide-1 (GLP-1) receptor agonists have recently received significant media coverage for their compelling efficacy in several indications. While most of the recent fanfare has been related to their role in weight loss, GLP-1 receptor agonists have been a mainstay of the type 2 diabetes treatment landscape for the past 2 decades. GLP-1 receptor agonists have also recently shown efficacy in reducing heart disease risk and treating certain chronic kidney diseases, which has opened the door to potential new indications and label expansions for this drug class. This symposium will explore the evolution of these and other agents (e.g. gastric inhibitory polypeptide [GIP] receptor agonists), including clinical efficacy and safety results, HCP and consumer perspectives, market adoption, and the access, reimbursement, and intellectual property (IP) landscapes. Speakers will include experts in drug discovery and development, and market research.

Symposium topics 

  • Diabetes / obesity and treatments
  • GLP-1 receptor agonists for diabetes and obesity: evolution and current marketed therapies, clinical efficacy and safety
  • GIP receptor agonists and dual GLP-1/GIP receptor agonists
  • Market landscape: revenues, HCP perspectives, consumer viewpoints, access and reimbursement
  • GLP-1 in other indications: CV, kidney disease, MASH
  • On the horizon: the obesity clinical pipeline, IP landscape, and the potential arrival of generics
Time (PST) Topic Presenter
11:30 – 11:45 am PBSS Welcome and Introduction Shichang Miao, PhD, PBSS
11:45 am – 1:00 pm How GLP-1 Receptor Agonists Evolved From Diabetes Treatments to Weight Loss Treatments Oliver Philps, PhD
1:00 – 1:45 pm So Much to Lose: Changing Landscape of Obesity in America Scott Morano, MBA
1:45 – 2:15 pm Panel Discussion Presenters


2024-08-14, [Free Online] Advances in Cancer Therapeutics (Organized by PBSS and BioScience Forum)
2024-09-10, [In-Person] Translational PK/PD and Human Dose Projection for Antibodies/ADCs and Novel Therapeutic Modalities
2024-09-20, [In-Person] Nonclinical Safety Assessments of Biologics and Other Novel Modalities for IND/NDA/BLA Filings
2024-09-25, [Free Online] Development of Protein Degraders: Computational Modeling, Medicinal Chemistry and Early Development
2024-10-10, [In-Person] Regulatory Global Submission: Strategies and Best Practices for FDA, EMA and PMDA
2024-10-25, [Free Online Workshop] Unleashing the Power of Real-World Evidence / Data (RWE/RWD) to Facilitate Drug Discovery, Development, and Beyond
2024-11-01, [In-Person] Clinical Pharmacology Studies on Hepatic and Renal Impairments for NDA Filing: Strategies, Design, Conduct, Analysis and Regulatory Aspects
2024-11-13, [Free Online Workshop] Career Transition for Research Scientists: Business Development & BioPartnering
2024-11-15, [In-Person] Bioanalysis for Biologics and Cell/Gene Therapy Products: Refining Established Approaches for New Complex Therapeutics
2025-01-22, [In-Person] Small-Molecule Formulation for Discovery & Early Development (jointly by PBSS / AAPS-BADG / Syner-G)
©Pharmaceutical & BioScience Society, International; Last Modified: 7/24/2024; Admin Logon
Ads (in random order)
Submit a Text Ad
($250 for 2 months)

Alturas Analytics, Inc. Expert Regulated & Non-Regulated LC-MS, GC-MS bioanalytical & PK/TK analysis of small & large molecules in any matrix. Discovery through phase IV.
Simulations Plus GastroPlus X: Science, models & refined algorithms—now with intuitive interface, faster processing & streamlined workflows for faster PBPK modeling.
Submit a Text Ad